Free Trial
→ 80X Growth in ONE Quarter (Read before June 16) (From Chaikin Analytics) (Ad)tc pixel Free IKT Stock Alerts

Inhibikase Therapeutics (IKT) Earnings Date, Estimates & Call Transcripts

Inhibikase Therapeutics logo
$1.67 +0.05 (+3.09%)
Closing price 06/9/2026 04:00 PM Eastern
Extended Trading
$1.69 +0.02 (+1.44%)
As of 06/9/2026 05:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

Inhibikase Therapeutics Earnings Summary

Inhibikase Therapeutics issued Q1 2026 earnings on May 12, 2026, reporting an EPS of -$0.10, which hit the consensus estimate of -$0.10. With a trailing EPS of -$0.43, Inhibikase Therapeutics' earnings are expected to decrease next year, from ($0.42) to ($0.44) per share.

Consensus EPS
(May. 12)
-$0.10
Actual EPS
(May. 12)
-$0.10

Q1 2026 Earnings Resources

Powered by Quartr
Get Inhibikase Therapeutics Earnings Alerts

Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Inhibikase Therapeutics and other key companies, straight to your inbox.

Sign Up
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.
Skip Charts & View Estimated and Actual Earnings Data

IKT Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

IKT Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Inhibikase Therapeutics Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20261-$0.10-$0.10-$0.10
Q2 20261-$0.10-$0.10-$0.10
Q3 20261-$0.11-$0.11-$0.11
Q4 20261-$0.11-$0.11-$0.11
FY 2026 4 -$0.42 -$0.42 -$0.42
Q1 20271-$0.13-$0.13-$0.13
Q2 20271-$0.13-$0.13-$0.13
Q3 20271-$0.12-$0.12-$0.12
Q4 20271-$0.11-$0.11-$0.11

Inhibikase Therapeutics Earnings History by Quarter

Export
DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails
5/12/2026Q1 2026-$0.10-$0.10--$0.10--
3/26/2026Q4 2025-$0.12-$0.09+$0.03-$0.09--
11/14/2025Q3 2025--$0.13--$0.13--
8/14/2024Q2 2024-$0.58-$0.66 -$0.08-$0.66--

Data powered by Fiscal.ai.

Inhibikase Therapeutics Earnings - Frequently Asked Questions

Inhibikase Therapeutics (NASDAQ:IKT) last announced its quarterly earning data on Tuesday, May 12, 2026. Learn more on IKT's earnings history.

In the previous quarter, Inhibikase Therapeutics (NASDAQ:IKT) reported ($0.10) earnings per share (EPS) to hit the analysts' consensus estimate of ($0.10). Learn more on analysts' earnings estimate vs. IKT's actual earnings.

Inhibikase Therapeutics (NASDAQ:IKT) has a recorded annual revenue of $260,000.00.

Inhibikase Therapeutics (NASDAQ:IKT) has a recorded net income of -$48.26 million. IKT has generated -$0.43 earnings per share over the last four quarters.

Inhibikase Therapeutics' earnings are expected to decrease from ($0.42) per share to ($0.44) per share in the next year.

Related Companies
Earnings Tools

This page (NASDAQ:IKT) was last updated on 6/10/2026 by MarketBeat.com Staff.
From Our Partners
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
The REAL Reason Trump is Invading Iran
For a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Be...
Banyan Hill Publishing | Sponsoredtc pixel
Trump's New Dollar
Porter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...
Porter & Company | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
In 30 days, you'll wish you'd read this email
A small power equipment company with $1.5 billion in orders is flying under the radar - but not for long. When...
Behind the Markets | Sponsoredtc pixel
This is the worst news for stocks in 50 years
Goldman Sachs and Morgan Stanley are issuing a rare warning: what's ahead for U.S. stocks could be the worst e...
TradeSmith | Sponsoredtc pixel
This IPO Could Make SpaceX Look Small (Read before June 16)
A red-hot AI startup just filed to go public - already valued at nearly $1 trillion. Wall Street veteran Marc ...
Chaikin Analytics | Sponsoredtc pixel